Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Do childhood vaccines last? 5-year follow-up study launched in china

NCT ID NCT07338851

Knowledge-focused Sponsor: China National Biotec Group Company Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 600 Chinese children who received standard vaccines against polio, measles, mumps, rubella, and hepatitis A. Researchers will test their blood to see if protective antibodies remain 5 years after vaccination. The goal is to understand how long vaccine protection lasts in real-world conditions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Sabin strain inactivated poliovirus vaccine, combined live attenuated measles, mumps and rubella vaccine, and freeze-dried live attenuated hepatitis A vaccine
What this could lead to
If successful, this study could confirm that these vaccines provide long-lasting protection, supporting current vaccination schedules.
What could go wrong
This is an observational follow-up study, not testing a new treatment. Results may show waning immunity over time, and findings may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants who have taken part in the NCT04638985 or NCT04636827 trials and have completed the designated batches of sIPV, MMR or HepA-L vaccinations, with a time interval of 60 to 66 months since the fourth dose of sIPV, the second dose of MMR or the first dose of HepA-L vaccination at the time of enrollment.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants in the NCT04638985 or NCT04636827, and who have completed the vaccination of designated batch numbers of sIPV, MMR or HepA-L vaccines; * The time window from the day of enrollment to the date when the participants received the fourth dose of sIPV vaccine, the second dose of MMR vaccine, or the first dose of HepA-L vaccine was 60 to 66 months. * The informed consent form shall be signed by the participant or his/her legal guardian and dated. Exclusion Criteria: * None.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatitis A are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatitis A virus infection measles mumps infectious disease poliomyelitis rubella

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatitis A Measles Mumps Polio Rubella

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chenggu County Center for Disease Control and Prevention

    Hanzhong, Shaanxi, China

  • Feixiang District Center for Disease Control and Prevention

    Handan, Hebei, China

  • Jiangyou Center for Disease Control and Prevention

    Mianyang, Sichuan, China

  • Sheyang County Center for Disease Control and Prevention

    Yancheng, Jiangsu, China

  • Si County Center for Disease Control and Prevention

    Suzhou, Anhui, China

  • Yanhu District Center for Disease Control and Prevention

    Yuncheng, Shanxi, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.